Is Mounjaro funded in New Zealand? PHARMAC status explained (updated Feb 2026)

Updated February 3, 2026. The short version: a medicine can have NZ medicine information and still not be publicly funded. PHARMAC funding decisions are separate and may involve consultation and eligibility criteria.

What we can confirm publicly

• PHARMAC advisory processes (including PTAC) discuss medicines and applications over time.
• Agendas and meeting material can mention medicines under consideration (including tirzepatide).
• A mention on an agenda is not the same as a funding decision.

What to watch for

• An official PHARMAC consultation or decision announcement.
• Any ‘special authority’ eligibility criteria if funding is approved.
• Whether funding is for diabetes, weight management, or both (these are treated differently).

If you’re waiting for funding

If medication would help your health now, it’s worth discussing current NZ options and a long‑term plan with a clinician. You don’t have to put your health on hold while funding decisions unfold.

Sources

• PHARMAC: PTAC overview (how advice works)
• PHARMAC: PTAC agenda mentioning tirzepatide (Mounjaro)
• Medsafe data sheet: Mounjaro (tirzepatide)